Contrasting effects of d-methamphetamine, 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats

Drug and Alcohol Dependence

Volumn 126, Issue 1-2, 2012, Pages 168-175

  Huang, Pai Kai ^a   Aarde, Shawn M ^a   Angrish, Deepshikha ^a   Houseknecht, Karen L ^b   Dickerson, Tobin J ^a   Taffe, Michael A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NEW ENGLAND   (United States)

Author keywords

Activity wheel; Bath salts; Cathinones; Ecstasy; Stimulants

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYPYROVALERONE; 4' METHYLMETHCATHINONE; METHAMPHETAMINE; PYROVALERONE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ABUSE; DRUG EFFECT; LOCOMOTION; MALE; MONOAMINERGIC SYSTEM; NERVE STIMULATION; NEUROCHEMISTRY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; RUNNING; WISTAR RAT;

ANIMALS; BENZODIOXOLES; CENTRAL NERVOUS SYSTEM STIMULANTS; DATA INTERPRETATION, STATISTICAL; DESIGNER DRUGS; DEXTROAMPHETAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; MALE; METHAMPHETAMINE; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PYRROLIDINES; RATS; RATS, WISTAR; STIMULATION, CHEMICAL;

MUSCOVY DUCK PARVOVIRUS; RATTUS; RATTUS NORVEGICUS;

EID: 84867841572     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.05.011     Document Type: Article

References (65)

1. Aarde S.M., Huang P.-K., Creehan K.M., Vaillancourt B.D., Vandewater S.A., Wright M.J., Miller M.L., Taffe M.A. Methylenedioxypyrovalerone (MDPV): self-administration and acute drug challenges in rats. FASEB J. 2012, 26:1040-1045.
2. Antonowicz J.L., Metzger A.K., Ramanujam S.L. Paranoid psychosis induced by consumption of methylenedioxypyrovalerone: two cases. Gen. Hosp. Psychiatry 2011, 33(640):e645-e646.
3. Bankson M.G., Cunningham K.A. Pharmacological studies of the acute effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-HT(1B/1D) and 5-HT(2) receptors. Neuropsychopharmacology 2002, 26:40-52.
4. Baumann M.H., Ayestas M.A., Partilla J.S., Sink J.R., Shulgin A.T., Daley P.F., Brandt S.D., Rothman R.B., Ruoho A.E., Cozzi N.V. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 2012, 37:1192-1203.
5. Baumann M.H., Clark R.D., Franken F.H., Rutter J.J., Rothman R.B. Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges. Neuroscience 2008, 152:773-784.
6. Baumann M.H., Clark R.D., Rothman R.B. Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain. Pharmacol. Biochem. Behav. 2008, 90:208-217.
7. Baumann M.H., Wang X., Rothman R.B. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berlin) 2007, 189:407-424.
8. Bluelight, 2006. MDPV Megathread. (accessed 03.01.12). http://ww.bluelight.ru/vb/threads/278421-MDPV-Megathread.
9. Bluelight, 2008. (RC's) Big mephedrone thread. (accessed 28.09.10). http://www.bluelight.ru/vb/showthread.php?t=400517.
10. Borek H.A., Holstege C.P. Hyperthermia and multiorgan failure after abuse of " bath salts" containing 3,4-methylenedioxypyrovalerone. Ann. Emerg. Med. 2012, (epub ahead of print).
11. Bradbury A.J., Costall B., Naylor R.J., Onaivi E.S. 5-Hydroxytryptamine involvement in the locomotor activity suppressant effects of amphetamine in the mouse. Psychopharmacology (Berlin) 1987, 93:457-465.
12. Brunt T.M., Poortman A., Niesink R.J., van den Brink W. Instability of the ecstasy market and a new kid on the block: mephedrone. J. Psychopharmacol. 2010, 25:1543-1547.
13. Bubar M.J., Pack K.M., Frankel P.S., Cunningham K.A. Effects of dopamine D1- or D2-like receptor antagonists on the hypermotive and discriminative stimulus effects of (+)-MDMA. Psychopharmacology (Berlin) 2004, 173:326-336.
14. Camilleri A., Johnston M.R., Brennan M., Davis S., Caldicott D.G.E. Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluoromethamphetamine, alpha-phthalimidopropiophenone and N-ethylcathinone. Forensic Sci. Int. 2010, 197:59-66.
15. Carhart-Harris R.L., King L.A., Nutt D.J. A web-based survey on mephedrone. Drug Alcohol Depend. 2011, 118:19-22.
16. Clark J.D., Gebhart G.F., Gonder J.C., Keeling M.E., Kohn D.F. Special report: the 1996 guide for the care and use of laboratory animals. ILAR J. 1997, 38:41-48.
17. Cosgrove K.P., Hunter R.G., Carroll M.E. Wheel-running attenuates intravenous cocaine self-administration in rats: sex differences. Pharmacol. Biochem. Behav. 2002, 73:663-671.
18. Crean R.D., Davis S.A., Taffe M.A. Oral administration of (+/-)3,4-methylenedioxymethamphetamine and (+)methamphetamine alters temperature and activity in rhesus macaques. Pharmacol. Biochem. Behav. 2007, 87:11-19.
19. Dargan P.I., Albert S., Wood D.M. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM 2010, 103:875-879.
20. De La Garza R., Fabrizio K.R., Gupta A. Relevance of rodent models of intravenous MDMA self-administration to human MDMA consumption patterns. Psychopharmacology (Berlin) 2006, 189:425-434.
21. DEA Request for information on synthetic cathones. Microgram Bull. 2011, 44:31-34.
22. DEA Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final Order. Federal Register 2011, 76:65371-65375.
23. Della Maggiore V., Ralph M.R. The effect of amphetamine on locomotion depends on the motor device utilized. The open field vs. the running wheel. Pharmacol. Biochem. Behav. 2000, 65:585-590.
24. Fantegrossi W.E., Bauzo R.M., Manvich D.M., Morales J.C., Votaw J.R., Goodman M.M., Howell L.L. Role of dopamine transporters in the behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in nonhuman primates. Psychopharmacology (Berlin) 2009, 205:337-347.
25. Fantegrossi W.E., Ciullo J.R., Wakabayashi K.T., De La Garza R., Traynor J.R., Woods J.H. A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse. Neuroscience 2008, 151:533-543.
26. Fuwa T., Fukamori N., Tanaka T., Kubo Y., Ogata A., Uehara S., Honda Y., Kodama T. Microdialysis study of drug effectgs on central nervous system - changes of dopamine levels in mice striatum after oral administration of methylenedioxypyrovalerone. Tokyo-to Kenko Anzen Kenkyu Senta Kenkyu Nenpo 2007, 58:287-292.
27. Geezaman, D.F., 2009. Surprisingly like E. (accessed 29.09.10). http://www.erowid.org/experiences/exp.php?ID=77952.
28. Gilpin N.W., Wright M.J., Dickinson G., Vandewater S.A., Price J.U., Taffe M.A. Influences of activity wheel access on the body temperature response to MDMA and methamphetamine. Pharmacol. Biochem. Behav. 2011, 99:295-300.
29. Gold L.H., Koob G.F. Methysergide potentiates the hyperactivity produced by MDMA in rats. Pharmacol. Biochem. Behav. 1988, 29:645-648.
30. Gold L.H., Koob G.F., Geyer M.A. Stimulant and hallucinogenic behavioral profiles of 3,4-methylenedioxymethamphetamine and N-ethyl-3,4-methylenedioxyamphetamine in rats. J. Pharmacol. Exp. Ther. 1988, 247:547-555.
31. Hadlock G.C., Webb K.M., McFadden L.M., Chu P.W., Ellis J.D., Allen S.C., Andrenyak D.M., Vieira-Brock P.L., German C.L., Conrad K.M., Hoonakker A.J., Gibb J.W., Wilkins D.G., Hanson G.R., Fleckenstein A.E. 4-Methylmethcathinone(mephedrone): neuropharmacological effects of a designer stimulant of abuse. J. Pharmacol. Exp. Ther. 2011, 339:530-536.
32. Haug M., Wallian L., Brain P.F. Effects of 8-OH-DPAT and fluoxetine on activity and attack by female mice towards lactating intruders. Gen. Pharmacol. 1990, 21:845-849.
33. Herin D.V., Liu S., Ullrich T., Rice K.C., Cunningham K.A. Role of the serotonin 5-HT2A receptor in the hyperlocomotive and hyperthermic effects of (+)-3,4-methylenedioxymethamphetamine. Psychopharmacology (Berlin) 2005, 178:505-513.
34. Hundt A.G., Premack D. Running as both a positive and negative reinforcer. Science 1963, 142:1087-1088.
35. Hurault de Ligny B., El Haggan W., Comoz F., Lobbedez T., Pujo M., Griveau A.M., Bottet P., Bensadoun H., Ryckelynck J.P. Early loss of two renal grafts obtained from the same donor: role of ecstasy?. Transplantation 2005, 80:153-156.
36. Iversen L., Adebowale V., Abdulrahim D., Arr-Jones G., Barnes M., Birtwistle M., Bray S., Carlin E., Clancy C., Crome I., Doran R., Gibbons S., Hargreaves P., Healy C., Hickman M., Measham F., Liddell D., Mathewson H., Pearce T., Philips J., Phillips R., Roberts H., Rowlands M., Tomlinson M., Wing A. Consideration of the Cathinones 2010, Advisory Council on the Misuse of Drugs.
37. Jansen K.L. Ecstasy (MDMA) dependence. Drug Alcohol Depend. 1999, 53:121-124.
38. Kehr J., Ichinose F., Yoshitake S., Goiny M., Sievertsson T., Nyberg F., Yoshitake T. Mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats. Br. J. Pharmacol. 2011, 164:1949-1958.
39. Kirkpatrick M.G., Gunderson E.W., Perez A.Y., Haney M., Foltin R.W., Hart C.L. A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berlin) 2012, 219:109-122.
40. Kitamura O., Wee S., Specio S.E., Koob G.F., Pulvirenti L. Escalation of methamphetamine self-administration in rats: a dose-effect function. Psychopharmacology (Berlin) 2006, 186:48-53.
41. Kouimtsidis C., Schifano F., Sharp T., Ford L., Robinson J., Magee C. Neurological and psychopathological sequelae associated with a lifetime intake of 40,000 ecstasy tablets. Psychosomatics 2006, 47:86-87.
42. Kyle P.B., Iverson R.B., Gajagowni R.G., Spencer L. Illicit bath salts: not for bathing. J. Miss. State Med. Assoc. 2011, 52:375-377.
43. Meltzer P.C., Butler D., Deschamps J.R., Madras B.K. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J. Med. Chem. 2006, 49:1420-1432.
44. MephTest, 2009. Good Alternative to MDMA. (accessed 29.09.10). http://www.erowid.org/experiences/exp.php?ID=82321.
45. Miller M.L., Vaillancourt B.D., Wright M.J., Aarde S.M., Vandewater S.A., Creehan K.M., Taffe M.A. Reciprocal inhibitory effects of intravenous d-methamphetamine self-administration and wheel activity in rats. Drug Alcohol Depend. 2012, 121:90-96.
46. Motbey C.P., Hunt G.E., Bowen M.T., Artiss S., McGregor I.S. Mephedrone (4-methylmethcathinone, 'meow'): acute behavioural effects and distribution of Fos expression in adolescent rats. Addict. Biol. 2011, 2:409-422.
47. Murray B.L., Murphy C.M., Beuhler M.C. Death following recreational use of designer drug " bath salts" containing 3,4-Methylenedioxypyrovalerone (MDPV). J. Med. Toxicol. 2012, 8:69-75.
48. Novak C.M., Burghardt P.R., Levine J.A. The use of a running wheel to measure activity in rodents: relationship to energy balance, general activity, and reward. Neurosci. Biobehav. Rev. 2012, 36(3):1001-1014.
49. O'Loinsigh E.D., Boland G., Kelly J.P., O'Boyle K.M. Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the Wistar rat. Prog. Neuropsychopharmacol. Biol. Psychiatry 2001, 25:621-638.
50. Orikabe L., Yamasue H., Inoue H., Takayanagi Y., Mozue Y., Sudo Y., Ishii T., Itokawa M., Suzuki M., Kurachi M., Okazaki Y., Kasai K. Reduced amygdala and hippocampal volumes in patients with methamphetamine psychosis. Schizophr. Res. 2011, 132:183-189.
51. Premack D., Schaeffer R.W., Hundt A. Reinforcement of drinking by running: effect of fixed ratio and reinforcement time. J. Exp. Anal. Behav. 1964, 7:91-96.
52. Reitzel L.A., Dalsgaard P.W., Muller I.B., Cornett C. Identification of ten new designer drugs by GC-MS, UPLC-QTOF-MS, and NMR as part of a police investigation of a Danish Internet company. Drug Test Anal. 2011, (epub ahead of print).
53. Ricaurte G.A., Forno L.S., Wilson M.A., DeLanney L.E., Irwin I., Molliver M.E., Langston J.W. (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA 1988, 260:51-55.
54. Rust K.Y., Baumgartner M.R., Dally A.M., Kraemer T. Prevalence of new psychoactive substances: a retrospective study in hair. Drug Test Anal. 2012, (epub ahead of print).
55. Sedefov R., Solberg U., Gallegos A., Almeida A. Europol-EMCDDA Joint Report on a New Psychoactive Substance: 4-methylmethcathinone (mephedrone) 2010, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal.
56. Sherwin C.M. Voluntary wheel running: a review and novel interpretation. Anim. Behav. 1998, 56:11-27.
57. Spiller H.A., Ryan M.L., Weston R.G., Jansen J. Clinical experience with and analytical confirmation of " bath salts" and " legal highs" (synthetic cathinones) in the United States. Clin. Toxicol. (Phila) 2011, 49:499-505.
58. Thornton S.L., Gerona R.R., Tomaszewski C.A. Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification. J. Med. Toxicol. 2012, (epub ahead of print).
59. Von Huben S.N., Lay C.C., Crean R.D., Davis S.A., Katner S.N., Taffe M.A. Impact of ambient temperature on hyperthermia induced by (+/-)3,4-methylenedioxymethamphetamine in rhesus macaques. Neuropsychopharmacology 2007, 32:673-681.
60. Walker Q.D., Morris S.E., Arrant A.E., Nagel J.M., Parylak S., Zhou G., Caster J.M., Kuhn C.M. Dopamine uptake inhibitors but not dopamine releasers induce greater increases in motor behavior and extracellular dopamine in adolescent rats than in adult male rats. J. Pharmacol. Exp. Ther. 2010, 335:124-132.
61. Weber M., Talmon S., Schulze I., Boeddinghaus C., Gross G., Schoemaker H., Wicke K.M. Running wheel activity is sensitive to acute treatment with selective inhibitors for either serotonin or norepinephrine reuptake. Psychopharmacology (Berlin) 2009, 203:753-762.
62. Winstock A., Mitcheson L., Ramsey J., Davies S., Puchnarewicz M., Marsden J. Mephedrone: use, subjective effects and health risks. Addiction 2011, 106:1991-1996.
63. Winstock A.R., Mitcheson L.R., Deluca P., Davey Z., Corazza O., Schifano F. Mephedrone, new kid for the chop?. Addiction 2011, 106:154-161.
64. Wright M.J., Angrish D., Aarde S.M., Creehan K.M., Vandewater S.A., Dickerson T.J., Taffe M.A. Effect of rat strain and ambient temperature on the hypothermic and locomotor stimulant effects of 4-methylmethcathinone (4-MMC). College on Problems of Drug Dependence, Annual Meeting 2011.
65. Yuan J., Hatzidimitriou G., Suthar P., Mueller M., McCann U., Ricaurte G. Relationship between temperature, dopaminergic neurotoxicity, and plasma drug concentrations in methamphetamine-treated squirrel monkeys. J. Pharmacol. Exp. Ther. 2006, 316:1210-1218.